Literature DB >> 8133464

Combined recirculation of the rat liver and kidney: studies with enalapril and enalaprilat.

I A de Lannoy1, K S Pang.   

Abstract

Combined recirculation of the rat liver (L) and kidney (IPK) at 10 ml min-1 per organ (LK) was developed to examine the hepatorenal handling of the precursor-metabolite pair: [14C]-enalapril and [3H]enalaprilat. Loading doses followed by constant infusion of [14C]enalapril and preformed [3H]enalaprilat to the reservoirs of the IPK or the LK preparation was used to achieve steady state conditions. In both organs, enalapril was mostly metabolized to its dicarboxylic acid metabolite, enalaprilat, which was excreted unchanged. At steady state, the fractional excretion for [14C]enalapril (FE = 0.45 to 0.48) and preformed [3H]enalaprilat (FE[pmi] = 1.1) were constant and similar for both the IPK and LK. The additivity of clearance was demonstrated in the LK preparation, namely, the total clearance of enalapril was the sum of its hepatic and renal clearances. However, the apparent fractional excretion for formed [14C]enalaprilat, FE(mi) and the apparent urinary clearance were time-dependent and higher than the corresponding values for preformed [3H]enalaprilat in both the IPK and LK. The FE(mi) and urinary clearance values further differed between the IPK and LK. Biliary clearance of formed vs. preformed enalaprilat displayed the same discrepant trends as observed for FE(mi) vs. FE(pmi) for the LK. These observations on the time-dependent and variable excretory clearance (urinary or biliary) of the formed metabolite vs. the constant, and much reduced, excretory clearance of the preformed metabolite are due to dual contributions to formed metabolite excretion: the nascently formed, intracellular metabolite which immediately underwent excretion and the formed metabolite which reentered the circulation, behaved as a preformed species. When data for the IPK and LK preparations were modeled with a physiological model with parameters previously reported for the L and IPK, all data, including metabolite excretory clearances, were well predicted. Model simulations revealed that the apparent FE(mi) differed between the LK and IPK preparations when the liver was present as an additional metabolite formation organ; the apparent excretory (urinary or biliary) clearance of the formed metabolite was further modulated by the volume of distribution of the metabolite, which altered levels of the formed, circulating metabolite.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8133464     DOI: 10.1007/bf01061690

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  25 in total

1.  Renal handling of enalapril and enalaprilat: studies in the isolated red blood cell-perfused rat kidney.

Authors:  I A de Lannoy; R Nespeca; K S Pang
Journal:  J Pharmacol Exp Ther       Date:  1989-12       Impact factor: 4.030

2.  Effects of perfusate flow rate on measured blood volume, disse space, intracellular water space, and drug extraction in the perfused rat liver preparation: characterization by the multiple indicator dilution technique.

Authors:  K S Pang; W F Lee; W F Cherry; V Yuen; J Accaputo; S Fayz; A J Schwab; C A Goresky
Journal:  J Pharmacokinet Biopharm       Date:  1988-12

3.  Improved function with amino acids in the isolated perfused kidney.

Authors:  F H Epstein; J T Brosnan; J D Tange; B D Ross
Journal:  Am J Physiol       Date:  1982-09

4.  Influence of acute renal failure on pharmacokinetics of phenolsulfonphthalein in rats: a comparative study in vivo and in the simultaneous perfusion system of liver and kidney.

Authors:  M Yasuhara; H Katayama; J Fujiwara; K Okumura; R Hori
Journal:  J Pharmacobiodyn       Date:  1985-05

5.  The physiological disposition and metabolism of enalapril maleate in laboratory animals.

Authors:  D J Tocco; F A deLuna; A E Duncan; T C Vassil; E H Ulm
Journal:  Drug Metab Dispos       Date:  1982 Jan-Feb       Impact factor: 3.922

6.  Kinetic modeling of the renal excretion of iodopyracet in the dog.

Authors:  P Hekman; C A van Ginneken
Journal:  J Pharmacokinet Biopharm       Date:  1982-02

7.  Selective vulnerability of the medullary thick ascending limb to anoxia in the isolated perfused rat kidney.

Authors:  M Brezis; S Rosen; P Silva; F H Epstein
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

Review 8.  Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease.

Authors:  B M Brenner; T W Meyer; T H Hostetter
Journal:  N Engl J Med       Date:  1982-09-09       Impact factor: 91.245

9.  The multiple-indicator dilution technique for characterization of normal and retrograde flow in once-through rat liver perfusions.

Authors:  M V St-Pierre; A J Schwab; C A Goresky; W F Lee; K S Pang
Journal:  Hepatology       Date:  1989-02       Impact factor: 17.425

10.  Formed and preformed metabolite excretion clearances in liver, a metabolite formation organ: studies on enalapril and enalaprilat in the single-pass and recirculating perfused rat liver.

Authors:  I A de Lannoy; F Barker; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1993-08
View more
  4 in total

1.  Organ clearance concepts: new perspectives on old principles.

Authors:  G L Sirianni; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1997-08

2.  Disposition of quinapril and quinaprilat in the isolated perfused rat kidney.

Authors:  A R Kugler; S C Olson; D E Smith
Journal:  J Pharmacokinet Biopharm       Date:  1995-06

3.  Formed and preformed metabolite excretion clearances in liver, a metabolite formation organ: studies on enalapril and enalaprilat in the single-pass and recirculating perfused rat liver.

Authors:  I A de Lannoy; F Barker; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1993-08

4.  Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat.

Authors:  David G Levitt; Rik C Schoemaker
Journal:  BMC Clin Pharmacol       Date:  2006-01-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.